Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | CFB | P00751 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596546 | 0.87 | MAP4K4 (0.37) | ARMAP4K4 | |
| SCHEMBL4596118 | 0.81 | MAP4K4 (0.51) | MAP4K4GRIN1GRIN2B | |
| SCHEMBL4597701 | 0.78 | KDM4E (0.50) | ARESRRALRRK2MRGPRX4S1PR1 | |
| SCHEMBL29956134 | 0.75 | ALDH1A1 (0.43) | ARLRRK2 | |
| SCHEMBL2460307 | 0.75 | ALDH1A1 (0.43) | ARLRRK2 | |
| SCHEMBL18570708 | 0.74 | SCN8A (0.49) | ARESRRATBXA2R | |
| SCHEMBL4598575 | 0.74 | HRH3 (0.46) | ARESRRAMRGPRX4PPARG | |
| SCHEMBL3689680 | 0.73 | KDM4E (0.44) | ARESRRA | |
| SCHEMBL17354630 | 0.72 | AR (0.44) | ARESRRALRRK2MRGPRX4S1PR1 | |
| SCHEMBL4597649 | 0.71 | AR (0.40) | ARLRRK2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | AR 1077/4885ESRRA 689/4885LRRK2 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.